GNLX insider buying and SEC filings, explained
Genelux Corp. · CIK 1231457
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$328K
Planned sales (10b5-1)
$109K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Aug 31, 2026 | Sale | Joseph Cappello (Chief Technical Officer) sold 10,257 shares at about $2.74 ($28K). Holdings down 3% to 318,480 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 2, 2026 |
| Aug 31, 2026 | Sale | Thomas Zindrick (CEO) sold 34,463 shares at about $2.67 ($92K). Holdings down 3% to 1,226,427 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 2, 2026 |
| Aug 31, 2026 | Sale | Yong Yu (Chief Scientific Officer) sold 9,683 shares at about $2.75 ($27K). Holdings down 4% to 258,688 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 2, 2026 |
| Aug 4, 2026 | Sale | Yong Yu (Chief Scientific Officer) sold 653 shares at about $2.94 ($2K). Holdings down <1% to 268,371 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 4, 2026 |
| Aug 4, 2026 | Sale | Joseph Cappello (Chief Technical Officer) sold 653 shares at about $2.95 ($2K). Holdings down <1% to 328,737 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 4, 2026 |
| Aug 4, 2026 | Sale | Thomas Zindrick (CEO) sold 3,023 shares at about $2.95 ($9K). Holdings down <1% to 1,260,890 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 4, 2026 |
| Jul 1, 2026 | Sale | John W Smither (Director) sold 12,000 shares at about $2.91 ($35K). Holdings down 12% to 91,403 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 2, 2026 |
| Jun 3, 2026 | Sale | Ralph Smalling (Head of Regulatory) sold 192 shares at $2.93 ($563). Holdings down <1% to 67,611 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 4, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | John Thomas (Director) sold 10,000 shares at about $2.98 ($30K), marked as a 10b5-1 plan trade. Holdings down 2% to 472,784 shares. | SEC filing Filed Jun 2, 2026 |
| May 11, 2026 | Sale | Joseph Cappello (Chief Technical Officer) sold 605 shares at about $2.97 ($2K). Holdings down <1% to 154,549 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 12, 2026 |
| May 11, 2026 | Sale | Yong Yu (Chief Scientific Officer) sold 605 shares at about $2.97 ($2K). Holdings down <1% to 149,706 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 12, 2026 |
| May 11, 2026 | Sale | Thomas Zindrick (CEO) sold 2,798 shares at about $2.94 ($8K). Holdings down 1% to 532,051 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 12, 2026 |
| May 11, 2026 | Sale | Ralph Smalling (Head of Regulatory) sold 270 shares at about $2.98 ($805). Holdings down <1% to 67,803 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 12, 2026 |
| Mar 24–25, 2026 | Sale | Ralph Smalling (Head of Regulatory) sold 585 shares between Mar 24 and Mar 25 at about $2.46 ($1K). Holdings down 1% to 68,073 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 26, 2026 |
| Mar 24, 2026 | Sale | Joseph Cappello (Chief Technical Officer) sold 906 shares at $2.42 ($2K). Holdings down 1% to 155,154 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 26, 2026 |
| Mar 24, 2026 | Sale | Yong Yu (SVP, Clinical Development) sold 906 shares at $2.42 ($2K). Holdings down 1% to 144,938 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 26, 2026 |
| Mar 24, 2026 | Sale | Thomas Zindrick (CEO) sold 3,582 shares at $2.42 ($9K). Holdings down 1% to 534,849 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 26, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | John Thomas (Director) sold 10,000 shares at about $2.90 ($29K), marked as a 10b5-1 plan trade. Holdings down 2% to 482,784 shares. | SEC filing Filed Mar 3, 2026 |
| Aug 21–Nov 17, 2025 | Sale | Thomas Zindrick (CEO) sold 17,182 shares between Aug 21, 2025 and Nov 17, 2025 at about $3.87 ($66K). Holdings down 3% to 538,431 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 11, 2025 |
| Aug 21–Nov 17, 2025 | Sale | Yong Yu (SVP, Clinical Development) sold 4,192 shares between Aug 21, 2025 and Nov 17, 2025 at about $3.83 ($16K). Holdings down 3% to 145,844 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 11, 2025 |
| Aug 21–Nov 17, 2025 | Sale | Joseph Cappello (Chief Technical Officer) sold 3,706 shares between Aug 21, 2025 and Nov 17, 2025 at about $3.88 ($14K). Holdings down 2% to 156,060 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 11, 2025 |
| Aug 21–Dec 5, 2025 | Sale | Ralph Smalling (Head of Regulatory) sold 2,332 shares between Aug 21, 2025 and Dec 5, 2025 at about $3.75 ($9K). Holdings down 3% to 68,658 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 9, 2025 |
| Dec 1, 2025 | Planned (10b5-1) | John Thomas (Director) sold 10,000 shares at about $5.00 ($50K), marked as a 10b5-1 plan trade. Holdings down 2% to 492,784 shares. | SEC filing Filed Dec 2, 2025 |
10 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow GNLX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.